# Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

> **NCT00052884** · PHASE1 · TERMINATED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 8 (actual)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** amifostine trihydrate
- **DRUG:** melphalan
- **PROCEDURE:** bone marrow ablation with stem cell support
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00052884
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01-22
- **Primary completion:** 2007-09
- **Final completion:** 2011-03
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow accrual and changes in clinical practice
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052884, "Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00052884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*